Trifluridine
Metastatic Microsatellite Stable Colon Carcinoma
Mayo ClinicSmall moleculePhase 1Active
CC
47/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the Metastatic Microsatellite Stable Colon Carcinoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
TIPIRACIL Mayo Clinic | Phase 1 | CC |
Polypepi1018 Mayo Clinic | Phase 1 | CC |
Same molecule, other indications
Trifluridine is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →